Annual vaccination is the most effective means of preventing and controlling influenza epidemics, and the traditional trivalent inactivated vaccine (TIV) is by far the most widely used. Unfortunately, it has a number of limitations, the most important of which is its poor immunogenicity in younger children and the elderly, the populations at greatest risk of severe influenza. Live attenuated influenza vaccine (LAIV) has characteristics that can overcome some of these limitations. It does not have to be injected because it is administered intranasally. It is very effective in children and adolescents, among whom it prevents significantly more cases of influenza than the traditional TIV. However, its efficacy in adults has not been adequately documented, which is why it has not been licensed for use by adults by the European health authorities. LAIV is safe and well tolerated by children aged > y and adults, but some concerns arisen regarding its safety in younger children and subjects with previous asthma or with recurrent wheezing. Further studies are needed to solve these problems and to evaluate the possible role of LAIV in the annual vaccination of the general population.
Live attenuated intranasal influenza vaccine / S. Esposito, V. Montinaro, E. Groppali, R. Tenconi, M. Semino, N. Principi. - In: HUMAN VACCINES & IMMUNOTHERAPEUTICS. - ISSN 2164-5515. - 8:1(2012), pp. 76-80.
|Titolo:||Live attenuated intranasal influenza vaccine|
ESPOSITO, SUSANNA (Primo)
PRINCIPI, NICOLA (Ultimo)
|Parole Chiave:||Children; Influenza; Influenza vaccination; Influenza vaccines; Pediatrics|
|Settore Scientifico Disciplinare:||Settore MED/38 - Pediatria Generale e Specialistica|
|Data di pubblicazione:||2012|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.4161/hv.8.1.18809|
|Appare nelle tipologie:||01 - Articolo su periodico|